Comparative Pharmacology
Head-to-head clinical analysis: LIMBITROL DS versus SERAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIMBITROL DS versus SERAX.
LIMBITROL DS vs SERAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Limbitrol DS is a combination of amitriptyline (a tricyclic antidepressant) and chlordiazepoxide (a benzodiazepine). Amitriptyline inhibits the reuptake of serotonin and norepinephrine, enhancing neurotransmission in the CNS. Chlordiazepoxide binds to GABA-A receptors, potentiating GABAergic inhibitory effects, leading to anxiolytic and sedative effects.
SERAX (oxazepam) is a benzodiazepine that modulates GABA-A receptors, enhancing the inhibitory effect of GABA, leading to anxiolytic, sedative, and anticonvulsant effects.
1 tablet (amitriptyline 25 mg/chlordiazepoxide 10 mg) orally 3 times daily initially, gradually increasing to 2 tablets orally 3 times daily or 3 tablets orally twice daily if needed; maximum 6 tablets per day.
Oral: 5-10 mg twice daily; maximum 20 mg/day. Intravenous: 2-5 mg slow IV push, may repeat after 2 hours.
None Documented
None Documented
Chlordiazepoxide: 5-30 hours (parent drug), active metabolite (desmethylchlordiazepoxide) 10-30 hours; amitriptyline: 13-36 hours (parent), nortriptyline (active metabolite) 18-44 hours. Half-lives increase with age and hepatic impairment.
Terminal elimination half-life is 8-15 hours (mean 12 hours) in adults; prolonged in renal impairment.
Renal: 70-80% as conjugated metabolites, <5% unchanged; fecal: 10-20% via biliary excretion.
Primarily renal (urinary) as unchanged drug (60-80%) and metabolites (20-40%); less than 5% fecal elimination.
Category C
Category C
Benzodiazepine/Tricyclic Antidepressant Combination
Benzodiazepine